Zelluna ASA Registers Share Capital Increase, Issuing 446,752 Shares to Inven2 AS

Zelluna ASA (OSE: ZLNA), a Norwegian biotechnology firm developing allogeneic T‑cell receptor‑based natural killer (...

Read story →